ADMA Biologics Announces First Commercial Sales of ASCENIV RAMSEY, N.J. and BOCA RATON, FL.

ADMA Biologics Announces First Commercial

RAMSEY, N.J. and BOCA RATON, FL., - October 21, 2019

- ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company

dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients

at risk for infection and the prevention of certain infectious diseases, today announced the first commercial sales of ASCENIV

(formerly known as RI-002). ASCENIV received approval from the U.S. Food and Drug Administration ("FDA") on April 1,

"The first commercial sales of ASCENIV, our third FDA-approved

product, marks another major milestone in ADMA's history," said Adam Grossman, President and Chief Executive Officer

of ADMA. "ASCENIV is a novel Intravenous Immune Globulin ("IVIG"), which is manufactured using our unique, patented

plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors

tested using our proprietary microneutralization assay. This proprietary biologic product is now commercially available for ordering

in the U.S. and we are actively working with our distribution partner, BioCare SD, and the physician community, to drive adoption

of ASCENIV for appropriate patients in the U.S. who could derive benefit."

ASCENIV is a plasma-derived, polyclonal human immune globulin

product. ASCENIV is indicated for the treatment of Primary Humoral Immunodeficiency or Primary Immune Deficiency Disease

("PI") in adults and adolescents (12 to 17 years of age). ASCENIV is protected by U.S. Patents: 9,107,906, 9,714,283

ASCENIV is now available and can be ordered through BioCare

SD, ADMA's authorized distributor. Prescribers and healthcare professionals interested in purchasing ASCENIV for use with

their PI patients should contact BioCare SD directly at 800-304-3064 or by visiting their website at www.BioCareSD.com.

Information about ASCENIV for healthcare professionals, patients

with primary immune deficiency disease and their healthcare partners can be found at: www.asceniv.com. Through the ASCENIV website,

physicians can access the prescription request form and request a meeting with a sales professional. Any medical or scientific

questions regarding ASCENIV, or any other products produced by ADMA, should be directed to the Medical Affairs Department at medicalaffairs@admabio.com

or 800-458-4244, prompt 2.

About Primary Immune Deficiency Disease ("PI")

PI is a class of inherited genetic disorders that causes an

individual to have a deficient or absent immune system. According to the World Health Organization, there are approximately 350

different genetic mutations encompassing PI. Some disorders present at birth or in early childhood, the disorders can affect anyone

regardless of age or gender. Some affect a single part of the immune system, others may affect one or more components of the system.

PI patients are vulnerable to infections and more likely to suffer complications from these infections as compared to individuals

with a normal functioning immune system. The infections may occur in any part of the body. Because patients suffering from PI lack

a properly functioning immune system, they typically receive monthly treatment with polyclonal immune globulin products. Without

this exogenous antibody replacement, these patients would remain vulnerable to persistent and chronic infections. PI has an estimated

prevalence of 1:1,200 in the United States, or approximately 250,000 people in the U.S.

About ASCENIV (Formerly RI-002)

ASCENIV, immune globulin intravenous, human - slra 10% liquid, is a plasma-derived, polyclonal, intravenous immune globulin

("IVIG"). ASCENIV was approved by the FDA on April 1, 2019 and is indicated for the treatment of Primary Humoral

Immunodeficiency or Primary Immune Deficiency Disease ("PI") in adults and adolescents (12 to 17 years of age). ASCENIV

is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which

blends normal source plasma and plasma from donors tested using the Company's proprietary microneutralization assay.

ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body's immune system

to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. ASCENIV prevented serious

bacterial infection among 59 patients treated for twelve months during the pivotal investigation. ASCENIV is protected by

U.S. Patents: 9,107,906, 9,714,283 and 9,815,886.

ASCENIV (immune globulin intravenous, human - slra) is

a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in

adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia,

common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies

WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE

Thrombosis may occur with immune globulin (IGIV) products,

including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous

or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.

Thrombosis may occur in the absence of known risk factors.

Renal dysfunction, acute renal failure, osmotic nephrosis,

and death may occur with the administration of Immune Globulin Intravenous (Human) (IGIV) products in predisposed patients.

Renal dysfunction and acute renal failure occur more commonly

in patients receiving IGIV products containing sucrose. ASCENIV does not contain sucrose.

For patients at risk of thrombosis, renal dysfunction or

renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before

administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

For additional safety information about ASCENIV, please see full

Prescribing Information.

ASCENIV is contraindicated in:

-Patients who have had an anaphylactic or severe systemic

reaction to the administration of human immune globulin.

-IgA-deficiency patients with antibodies to IgA and a history

of hypersensitivity.

Warnings and Precautions

Severe hypersensitivity reactions may occur with IGIV products,

including ASCENIV. In case of hypersensitivity, discontinue ASCENIV infusion immediately and institute appropriate treatment. Patients

with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

Thrombosis may occur following treatment with immunoglobulin

products and in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity

and ensure adequate hydration before administration. For patients at risk of thrombosis, administer ASCENIV at the minimum dose

and infusion rate practicable. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for

Acute renal dysfunction/failure, osmotic nephrosis, and death

may occur upon use of human IGIV products. Ensure that patients are not volume depleted before administering ASCENIV. Periodic

monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing

acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the

initial infusion of ASCENIV and at appropriate intervals thereafter. Discontinue ASCENIV if renal function deteriorates. In at

risk patients, administer ASCENIV at the minimum infusion rate practicable.

Hyperproteinemia, increased serum viscosity, and hyponatremia

or pseudohyponatremia may occur in patients receiving IGIV treatment, including ASCENIV. It is critical to clinically distinguish

true hyponatremia from a pseudohyponatremia that is associated with or causally related to hyperproteinemia. Treatment aimed at

decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity,

and a possible predisposition to thrombotic events.

Aseptic meningitis syndrome (AMS) may occur with IGIV treatments,

including ASCENIV. AMS usually begins within several hours to 2 days following IGIV treatment. AMS may occur more frequently in

association with high doses (2 g/kg) and/or rapid infusion of IGIV. Conduct a thorough neurological examination on patients exhibiting

signs and symptoms of AMS, including cerebrospinal fluid (CSF) studies, to rule out other causes of meningitis.

IGIV products, including ASCENIV, may contain blood group antibodies

that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct

antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis, including appropriate confirmatory

Non-cardiogenic pulmonary edema may occur with IV administered

IG. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil in

both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Because ASCENIV is made from human blood, it may carry a risk

of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob

disease (CJD) agent. All infections suspected by a physician to possibly have been transmitted by this product should be reported

to ADMA Biologics at (1-800-458-4244).